Published in Eur J Nucl Med Mol Imaging on April 01, 2005
Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI). Alzheimers Dement (2005) 7.90
Ageing and neuronal vulnerability. Nat Rev Neurosci (2006) 3.36
Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias. J Nucl Med (2008) 2.92
Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer's Disease Neuroimaging Initiative (ADNI). Neuroimage (2009) 2.80
Maternal family history of Alzheimer's disease predisposes to reduced brain glucose metabolism. Proc Natl Acad Sci U S A (2007) 2.41
The amyloid beta-peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae. Proc Natl Acad Sci U S A (2008) 2.30
Subregional hippocampal atrophy predicts Alzheimer's dementia in the cognitively normal. Neurobiol Aging (2008) 2.25
FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease. Eur J Nucl Med Mol Imaging (2009) 2.15
The use of PET in Alzheimer disease. Nat Rev Neurol (2010) 2.13
Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease. Eur J Nucl Med Mol Imaging (2008) 2.04
Comparison of 18F-FDG and PiB PET in cognitive impairment. J Nucl Med (2009) 1.90
Hippocampal hypometabolism predicts cognitive decline from normal aging. Neurobiol Aging (2007) 1.90
Imaging markers for Alzheimer disease: which vs how. Neurology (2013) 1.76
Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer's disease. Ann N Y Acad Sci (2008) 1.64
Partial volume effect-corrected FDG PET and grey matter volume loss in patients with mild Alzheimer's disease. Eur J Nucl Med Mol Imaging (2007) 1.58
Diagnosis and treatment of dementia: 2. Diagnosis. CMAJ (2008) 1.55
Multimodality Review of Amyloid-related Diseases of the Central Nervous System. Radiographics (2016) 1.53
Longitudinal brain metabolic changes from amnestic mild cognitive impairment to Alzheimer's disease. Brain (2009) 1.50
Nanomedicine in the diagnosis and therapy of neurodegenerative disorders. Prog Polym Sci (2007) 1.41
Potential therapeutic benefits of strategies directed to mitochondria. Antioxid Redox Signal (2010) 1.40
A ketone ester diet exhibits anxiolytic and cognition-sparing properties, and lessens amyloid and tau pathologies in a mouse model of Alzheimer's disease. Neurobiol Aging (2012) 1.32
Type 2 diabetes and cognitive impairment: linking mechanisms. J Alzheimers Dis (2012) 1.28
Pre-clinical detection of Alzheimer's disease using FDG-PET, with or without amyloid imaging. J Alzheimers Dis (2010) 1.28
Neuroimaging and other biomarkers for Alzheimer's disease: the changing landscape of early detection. Annu Rev Clin Psychol (2013) 1.28
Mapping progressive brain structural changes in early Alzheimer's disease and mild cognitive impairment. Neuropsychologia (2007) 1.26
Experimental diabetes mellitus exacerbates tau pathology in a transgenic mouse model of Alzheimer's disease. PLoS One (2009) 1.23
Relative capability of MR imaging and FDG PET to depict changes associated with prodromal and early Alzheimer disease. Radiology (2010) 1.22
Strategies for molecular imaging dementia and neurodegenerative diseases. Neuropsychiatr Dis Treat (2008) 1.21
Cerebral perfusion correlates of conversion to Alzheimer's disease in amnestic mild cognitive impairment. J Neurol (2007) 1.16
Latent feature representation with stacked auto-encoder for AD/MCI diagnosis. Brain Struct Funct (2013) 1.16
Disrupted small-world brain networks in moderate Alzheimer's disease: a resting-state FMRI study. PLoS One (2012) 1.15
Prolonged oral cannabinoid administration prevents neuroinflammation, lowers β-amyloid levels and improves cognitive performance in Tg APP 2576 mice. J Neuroinflammation (2012) 1.15
Mild cognitive impairment: baseline and longitudinal structural MR imaging measures improve predictive prognosis. Radiology (2011) 1.13
Hierarchical feature representation and multimodal fusion with deep learning for AD/MCI diagnosis. Neuroimage (2014) 1.13
Mitochondrial respiratory inhibition and oxidative stress elevate beta-secretase (BACE1) proteins and activity in vivo in the rat retina. Exp Brain Res (2007) 1.12
Maternal transmission of Alzheimer's disease: prodromal metabolic phenotype and the search for genes. Hum Genomics (2010) 1.12
Noninvasive brain stimulation in Alzheimer's disease: systematic review and perspectives for the future. Exp Gerontol (2011) 1.12
Mapping brain morphological and functional conversion patterns in amnestic MCI: a voxel-based MRI and FDG-PET study. Eur J Nucl Med Mol Imaging (2010) 1.10
Identifying cognitively healthy elderly individuals with subsequent memory decline by using automated MR temporoparietal volumes. Radiology (2011) 1.09
Comparison of the diagnostic performance of FDG-PET and VBM-MRI in very mild Alzheimer's disease. Eur J Nucl Med Mol Imaging (2006) 1.08
Current Challenges for the Early Detection of Alzheimer's Disease: Brain Imaging and CSF Studies. J Clin Neurol (2009) 1.06
Involvement of astroglial ceramide in palmitic acid-induced Alzheimer-like changes in primary neurons. Eur J Neurosci (2007) 1.06
Increased regional cerebral glucose uptake in an APP/PS1 model of Alzheimer's disease. Neurobiol Aging (2011) 1.06
Visual rating of medial temporal lobe metabolism in mild cognitive impairment and Alzheimer's disease using FDG-PET. Eur J Nucl Med Mol Imaging (2005) 1.03
Reduced FDG-PET brain metabolism and executive function predict clinical progression in elderly healthy subjects. Neuroimage Clin (2013) 1.02
Summary metrics to assess Alzheimer disease-related hypometabolic pattern with 18F-FDG PET: head-to-head comparison. J Nucl Med (2012) 1.02
Movement correction method for human brain PET images: application to quantitative analysis of dynamic 18F-FDDNP scans. J Nucl Med (2010) 1.01
Regional cortical thickness and subcortical volume changes are associated with cognitive impairments in the drug-naive patients with late-onset depression. Neuropsychopharmacology (2011) 0.99
Insulin in the brain: its pathophysiological implications for States related with central insulin resistance, type 2 diabetes and Alzheimer's disease. Front Endocrinol (Lausanne) (2014) 0.98
Mitochondrial alterations near amyloid plaques in an Alzheimer's disease mouse model. J Neurosci (2013) 0.98
Framingham cardiovascular risk profile correlates with impaired hippocampal and cortical vasoreactivity to hypercapnia. J Cereb Blood Flow Metab (2010) 0.97
Mitochondria in neurodegeneration. Adv Exp Med Biol (2012) 0.97
Quantitative structural MRI for early detection of Alzheimer's disease. Expert Rev Neurother (2010) 0.96
The epidemiology of delirium: challenges and opportunities for population studies. Am J Geriatr Psychiatry (2013) 0.96
Relationship between baseline brain metabolism measured using [¹⁸F]FDG PET and memory and executive function in prodromal and early Alzheimer's disease. Brain Imaging Behav (2012) 0.96
Amyloid and metabolic positron emission tomography imaging of cognitively normal adults with Alzheimer's parents. Neurobiol Aging (2012) 0.96
Brain SPECT in subtypes of mild cognitive impairment. Findings from the DESCRIPA multicenter study. J Neurol (2008) 0.95
Beneficial network effects of methylene blue in an amnestic model. Neuroimage (2010) 0.94
Altered medial temporal lobe responses during visuospatial encoding in healthy APOE*4 carriers. Neurobiol Aging (2007) 0.94
Imaging biomarkers associated with cognitive decline: a review. Biol Psychiatry (2014) 0.94
Neuroimaging of individuals with Down's syndrome at-risk for dementia: evidence for possible compensatory events. Neuroimage (2007) 0.93
Glucose metabolism during resting state reveals abnormal brain networks organization in the Alzheimer's disease and mild cognitive impairment. PLoS One (2013) 0.93
Role of mitochondrial homeostasis and dynamics in Alzheimer's disease. Neurobiol Dis (2012) 0.93
Neuroimaging biomarkers of neurodegenerative diseases and dementia. Semin Neurol (2013) 0.92
Is Alzheimer's disease a systemic disease? Biochim Biophys Acta (2014) 0.92
18F-fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E genotype in cognitively normal persons. Neurobiol Aging (2014) 0.92
Glucose metabolism in normal aging and Alzheimer's disease: Methodological and physiological considerations for PET studies. Clin Transl Imaging (2013) 0.91
Oxidative modification of lipoic acid by HNE in Alzheimer disease brain. Redox Biol (2013) 0.91
Brain metabolic maps in Mild Cognitive Impairment predict heterogeneity of progression to dementia. Neuroimage Clin (2014) 0.91
Dissociation between brain amyloid deposition and metabolism in early mild cognitive impairment. PLoS One (2012) 0.90
Human apolipoprotein E ɛ4 expression impairs cerebral vascularization and blood-brain barrier function in mice. J Cereb Blood Flow Metab (2014) 0.90
Alzheimer's disease markers, hypertension, and gray matter damage in normal elderly. Neurobiol Aging (2011) 0.90
The Basic Biology of BACE1: A Key Therapeutic Target for Alzheimer's Disease. Curr Genomics (2007) 0.90
Neurobiology of Alzheimer's Disease: Integrated Molecular, Physiological, Anatomical, Biomarker, and Cognitive Dimensions. Curr Alzheimer Res (2015) 0.90
Early detection of Alzheimer's disease with PET imaging. Neurodegener Dis (2010) 0.90
Tensor-based morphometry with stationary velocity field diffeomorphic registration: application to ADNI. Neuroimage (2010) 0.90
What have novel imaging techniques revealed about metabolism in the aging brain? Future Neurol (2014) 0.89
Mitochondria, cognitive impairment, and Alzheimer's disease. Int J Alzheimers Dis (2009) 0.89
Cerebrospinal fluid biomarkers of Alzheimer's disease in healthy elderly. Front Biosci (Landmark Ed) (2013) 0.89
PET/CT in diagnosis of dementia. Ann N Y Acad Sci (2011) 0.89
Early decline in glucose transport and metabolism precedes shift to ketogenic system in female aging and Alzheimer's mouse brain: implication for bioenergetic intervention. PLoS One (2013) 0.88
Age-dependent modulation of synaptic plasticity and insulin mimetic effect of lipoic acid on a mouse model of Alzheimer's disease. PLoS One (2013) 0.88
In Alzheimer's Disease, 6-Month Treatment with GLP-1 Analog Prevents Decline of Brain Glucose Metabolism: Randomized, Placebo-Controlled, Double-Blind Clinical Trial. Front Aging Neurosci (2016) 0.87
Latrepirdine: molecular mechanisms underlying potential therapeutic roles in Alzheimer's and other neurodegenerative diseases. Transl Psychiatry (2013) 0.87
Bayesian network analysis reveals alterations to default mode network connectivity in individuals at risk for Alzheimer's disease. PLoS One (2013) 0.87
Translational gene mapping of cognitive decline. Neurobiol Aging (2006) 0.87
Obesity, insulin resistance, and Alzheimer's disease. Obesity (Silver Spring) (2012) 0.87
Enhanced expression of three monocarboxylate transporter isoforms in the brain of obese mice. J Physiol (2007) 0.87
In vivo measurement of glutamate loss is associated with synapse loss in a mouse model of tauopathy. Neuroimage (2014) 0.87
Ovariectomy induces a shift in fuel availability and metabolism in the hippocampus of the female transgenic model of familial Alzheimer's. PLoS One (2013) 0.86
White Matter Lipids as a Ketogenic Fuel Supply in Aging Female Brain: Implications for Alzheimer's Disease. EBioMedicine (2015) 0.86
Activity of P-Glycoprotein, a β-Amyloid Transporter at the Blood-Brain Barrier, Is Compromised in Patients with Mild Alzheimer Disease. J Nucl Med (2014) 0.86
Current status and future role of brain PET/MRI in clinical and research settings. Eur J Nucl Med Mol Imaging (2015) 0.86
FDG- and amyloid-PET in Alzheimer's disease: is the whole greater than the sum of the parts? Q J Nucl Med Mol Imaging (2011) 0.86
A survey of FDG- and amyloid-PET imaging in dementia and GRADE analysis. Biomed Res Int (2014) 0.85
Subclass-based multi-task learning for Alzheimer's disease diagnosis. Front Aging Neurosci (2014) 0.84
Parkin-mediated mitophagy in mutant hAPP neurons and Alzheimer's disease patient brains. Hum Mol Genet (2015) 0.84
Human ApoE Isoforms Differentially Modulate Glucose and Amyloid Metabolic Pathways in Female Brain: Evidence of the Mechanism of Neuroprotection by ApoE2 and Implications for Alzheimer's Disease Prevention and Early Intervention. J Alzheimers Dis (2015) 0.84
Imaging Multimodalities for Dissecting Alzheimer's Disease: Advanced Technologies of Positron Emission Tomography and Fluorescence Imaging. Front Neurosci (2015) 0.84
Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology (1984) 119.59
Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (1991) 49.03
Mild cognitive impairment: clinical characterization and outcome. Arch Neurol (1999) 33.06
Current concepts in mild cognitive impairment. Arch Neurol (2001) 18.09
Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A (1993) 15.04
Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol (1991) 14.25
The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry (1982) 10.83
Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med (1996) 10.60
Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol (1999) 10.45
Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol (1997) 10.06
Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology (1999) 9.86
What is cognitive reserve? Theory and research application of the reserve concept. J Int Neuropsychol Soc (2002) 9.81
Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health (1998) 9.58
Leisure activities and the risk of dementia in the elderly. N Engl J Med (2003) 8.77
Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease. Neurology (1997) 8.50
Influence of education and occupation on the incidence of Alzheimer's disease. JAMA (1994) 8.43
Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology (2001) 7.68
Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology (2001) 7.51
Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J Neurosci (1996) 7.19
Alzheimer's disease: cell-specific pathology isolates the hippocampal formation. Science (1984) 6.86
Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc Natl Acad Sci U S A (2003) 6.46
Functional connectivity: the principal-component analysis of large (PET) data sets. J Cereb Blood Flow Metab (1993) 6.20
Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch Neurol (1998) 5.93
Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD. Neurology (2004) 5.86
Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. JAMA (2001) 5.13
Rates of hippocampal atrophy correlate with change in clinical status in aging and AD. Neurology (2000) 4.89
MR-based hippocampal volumetry in the diagnosis of Alzheimer's disease. Neurology (1992) 4.87
Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in U.S. population aged 20-74 yr. Diabetes (1987) 4.86
Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A (2000) 4.85
Comparing functional (PET) images: the assessment of significant change. J Cereb Blood Flow Metab (1991) 4.69
Education and the prevalence of dementia and Alzheimer's disease. Neurology (1993) 4.68
MRI measures of entorhinal cortex vs hippocampus in preclinical AD. Neurology (2002) 4.67
Presymptomatic hippocampal atrophy in Alzheimer's disease. A longitudinal MRI study. Brain (1996) 4.61
MRI-derived entorhinal and hippocampal atrophy in incipient and very mild Alzheimer's disease. Neurobiol Aging (2001) 4.54
Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease. Neurology (1992) 4.52
Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia. Neurology (2002) 4.50
A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med (1995) 4.44
Volume loss of the hippocampus and temporal lobe in healthy elderly persons destined to develop dementia. Neurology (1997) 4.35
Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease. Proc Natl Acad Sci U S A (2001) 4.26
Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA (1995) 4.02
Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage (2002) 3.88
Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET). Proc Natl Acad Sci U S A (2001) 3.86
Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. JAMA (1995) 3.84
Energy on demand. Science (1999) 3.80
Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease. Arch Neurol (2001) 3.80
Alzheimer's disease: genotypes, phenotypes, and treatments. Science (1997) 3.72
Mild cognitive impairment: Can FDG-PET predict who is to rapidly convert to Alzheimer's disease? Neurology (2003) 3.60
Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study. Eur J Nucl Med Mol Imaging (2003) 3.50
The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease. Neurology (1999) 3.49
Patterns of temporal lobe atrophy in semantic dementia and Alzheimer's disease. Ann Neurol (2001) 3.43
The histological validation of post mortem magnetic resonance imaging-determined hippocampal volume in Alzheimer's disease. Neuroscience (2000) 3.40
Computer-assisted imaging to assess brain structure in healthy and diseased brains. Lancet Neurol (2003) 3.26
Hippocampal formation glucose metabolism and volume losses in MCI and AD. Neurobiol Aging (2001) 3.25
Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies. Am J Psychiatry (2002) 3.20
Automatic differentiation of anatomical patterns in the human brain: validation with studies of degenerative dementias. Neuroimage (2002) 3.06
Medial temporal lobe atrophy and memory dysfunction as predictors for dementia in subjects with mild cognitive impairment. J Neurol (1999) 2.92
Neuropathological and neuropsychological changes in "normal" aging: evidence for preclinical Alzheimer disease in cognitively normal individuals. J Neuropathol Exp Neurol (1998) 2.92
Atrophy of the medial occipitotemporal, inferior, and middle temporal gyri in non-demented elderly predict decline to Alzheimer's disease. Neurobiol Aging (2000) 2.80
Quantification of magnetic resonance scans for hippocampal and parahippocampal atrophy in Alzheimer's disease. Neurology (1991) 2.77
Brain atrophy progression measured from registered serial MRI: validation and application to Alzheimer's disease. J Magn Reson Imaging (1998) 2.75
FDG PET imaging in patients with pathologically verified dementia. J Nucl Med (2000) 2.70
Independent predictors of cognitive decline in healthy elderly persons. Arch Neurol (2002) 2.70
Frequency of hippocampal formation atrophy in normal aging and Alzheimer's disease. Neurobiol Aging (1997) 2.68
Specific hippocampal volume reductions in individuals at risk for Alzheimer's disease. Neurobiol Aging (1997) 2.66
The role of cortical connectivity in Alzheimer's disease pathogenesis: a review and model system. Neurobiol Aging (1993) 2.65
Mild cognitive impairment: prevalence, prognosis, aetiology, and treatment. Lancet Neurol (2003) 2.63
Inverse relationship between education and parietotemporal perfusion deficit in Alzheimer's disease. Ann Neurol (1992) 2.59
Decreased concentrations of GLUT1 and GLUT3 glucose transporters in the brains of patients with Alzheimer's disease. Ann Neurol (1994) 2.54
Hippocampal volumes in cognitively normal persons at genetic risk for Alzheimer's disease. Ann Neurol (1998) 2.48
The radiologic prediction of Alzheimer disease: the atrophic hippocampal formation. AJNR Am J Neuroradiol (1993) 2.44
The dementias. Lancet (2002) 2.42
Neuroplasticity failure in Alzheimer's disease: bridging the gap between plaques and tangles. Neuron (1999) 2.30
Limbic hypometabolism in Alzheimer's disease and mild cognitive impairment. Ann Neurol (2003) 2.26
Hippocampal volume losses in minimally impaired elderly. Lancet (1995) 2.26
Association of premorbid intellectual function with cerebral metabolism in Alzheimer's disease: implications for the cognitive reserve hypothesis. Am J Psychiatry (1997) 2.25
Regional glucose metabolic abnormalities are not the result of atrophy in Alzheimer's disease. Neurology (1998) 2.24
Relationship between lifetime occupation and parietal flow: implications for a reserve against Alzheimer's disease pathology. Neurology (1995) 2.24
Temporal lobe regions on magnetic resonance imaging identify patients with early Alzheimer's disease. Arch Neurol (1993) 2.17
New frontiers in Alzheimer's disease genetics. Neuron (2001) 2.17
Altered glucose metabolism in microvessels from patients with Alzheimer's disease. Ann Neurol (1989) 2.08
MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET. Neurology (2004) 2.07
Prevalence of Alzheimer's disease and other dementias in an elderly urban population: relationship with age, sex, and education. Neurology (1991) 2.05
Early marker for Alzheimer's disease: the atrophic hippocampus. Lancet (1989) 2.02
Molecular genetics of Alzheimer's disease. Biol Psychiatry (2000) 1.99
Positron emission tomography: human brain function and biochemistry. Science (1985) 1.92
MRI of entorhinal cortex in mild Alzheimer's disease. Lancet (1999) 1.86
Development of Alzheimer-related neurofibrillary changes in the neocortex inversely recapitulates cortical myelogenesis. Acta Neuropathol (1996) 1.83
Amyloid beta-peptide impairs glucose transport in hippocampal and cortical neurons: involvement of membrane lipid peroxidation. J Neurosci (1997) 1.79
Alzheimer changes in nondemented patients younger than sixty-five: possible early stages of Alzheimer's disease and senile dementia of Alzheimer type. Ann Neurol (1985) 1.75
A new definition of Alzheimer's disease: a hippocampal dementia. Lancet (1985) 1.73
Altered tau and neurofilament proteins in neuro-degenerative diseases: diagnostic implications for Alzheimer's disease and Lewy body dementias. Brain Pathol (1993) 1.72
Serial magnetic resonance imaging of cerebral atrophy in preclinical Alzheimer's disease. Lancet (1999) 1.68
Alzheimer's disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation. Ann Neurol (2001) 1.67
Differentiating frontal and temporal variant frontotemporal dementia from Alzheimer's disease. Neurology (2000) 1.63
Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment. Neuroreport (2001) 1.63
Hippocampal abnormalities in amnesic patients revealed by high-resolution magnetic resonance imaging. Nature (1989) 1.58
Cortical abnormalities in Alzheimer's disease. Ann Neurol (1984) 1.57
Beta-amyloid increases neuronal susceptibility to injury by glucose deprivation. Neuroreport (1991) 1.55
Volumes of the entorhinal and perirhinal cortices in Alzheimer's disease. Neurobiol Aging (1998) 1.53